Delta(9) -tetrahydrocannabinol and cannabidiol as potential curative agents for cancer: A critical examination of the preclinical literature

Clin Pharmacol Ther. 2015 Jun;97(6):587-96. doi: 10.1002/cpt.84. Epub 2015 May 2.

Abstract

An Internet search with search words "cannabis cures cancer" produce a wealth of sites claiming that cannabis has this effect. These sites are freely accessible to the general public and thus contribute to public opinion. But do delta(9) -tetrahydrocannabinol (Δ(9) -THC) and cannabidiol (CBD) cure cancer? In the absence of clinical data other than a safety study and case reports, preclinical data should be evaluated in terms of its predictive value. Using a strict approach where only concentrations and/or models relevant to the clinical situation are considered, the current preclinical data do not yet provide robust evidence that systemically administered Δ(9) -THC will be useful for the curative treatment of cancer. There is more support for an intratumoral route of administration of higher doses of Δ(9) -THC. CBD produces effects in relevant concentrations and models, although more data are needed concerning its use in conjunction with other treatment strategies.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Cannabidiol / pharmacology
  • Cannabidiol / therapeutic use*
  • Cell Survival / drug effects
  • Dronabinol / pharmacology
  • Dronabinol / therapeutic use*
  • Humans
  • Neoplasms / drug therapy*
  • Neoplasms / pathology
  • Receptors, Cannabinoid / analysis
  • Receptors, Cannabinoid / physiology

Substances

  • Receptors, Cannabinoid
  • Cannabidiol
  • Dronabinol